clavulanic acid has been researched along with Extensively Drug-Resistant Tuberculosis in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 11 (91.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clumeck, N; De Wit, S; Delforge, M; Mathys, V; Muylle, I; Payen, MC; Van den Wijngaert, S; Vandenberg, O | 1 |
| Bethel, CR; Blanchard, JS; Bonomo, RA; Hazra, S; Hujer, AM; Kurz, SG; Nguyen, L; Smith, KM; Tremblay, LW; Wolff, KA; Xu, Y | 1 |
| Cufré, M; García, A; González Montaner, P; Palmero, D; Poggi, S; Vescovo, M | 1 |
| Caminero, JA; Scardigli, A | 1 |
| Akkerman, OW; Alarcon Arrascue, E; Alarcon Guizado, V; Aleksa, A; Alffenaar, JW; Arbex, MA; Artsukevich, J; Avchinko, V; Bonini, EH; Caminero, JA; Centis, R; Chong Marín, FA; Collahuazo López, L; D'Ambrosio, L; De Lorenzo, S; de Vries, G; Dore, S; Gaga, M; Gualano, G; Kunst, H; Matteelli, A; Migliori, GB; Moschos, C; Palmieri, F; Papavasileiou, A; Payen, MC; Piana, A; Roby Arias, AJ; Scardigli, A; Skrahina, A; Solovic, I; Sotgiu, G; Spanevello, A; Sulis, G; Tadolini, M; Tiberi, S; Vargas Vasquez, D; Viggiani, P; White, V; Zumla, A | 1 |
| Abdo Arbex, M; Akkerman, OW; Alarcon Arrascue, E; Alarcon Guizado, V; Aleska, A; Alffenaar, JW; Avchinko, V; Bonini, EH; Caminero, JA; Centis, R; Chong Marín, FA; Collahuazo López, L; D'Ambrosio, L; De Lorenzo, S; de Vries, G; Dore, S; Gaga, M; Gualano, G; Kunst, H; Matteelli, A; Migliori, GB; Moschos, C; Palmieri, F; Papavasileiou, A; Payen, MC; Roby Arias, AJ; Scardigli, A; Skrahina, A; Solovic, I; Sotgiu, G; Spanevello, A; Sulis, G; Tadolini, M; Tiberi, S; Vargas Vasquez, D; Viggiani, P; White, V; Zumla, A | 1 |
| Abdo Arbex, M; Akkerman, OW; Alarcon Arrascue, E; Alarcon Guizado, V; Aleksa, A; Alffenaar, JW; Artsukevich, J; Auchynka, V; Bonini, EH; Caminero, JA; Centis, R; Chong Marín, FA; Collahuazo López, L; D'Ambrosio, L; De Lorenzo, S; de Vries, G; Dore, S; Gaga, M; Gualano, G; Kunst, H; Matteelli, A; Migliori, GB; Moschos, C; Palmieri, F; Papavasileiou, A; Payen, MC; Piana, A; Roby Arias, AJ; Scardigli, A; Skrahina, A; Solovic, I; Sotgiu, G; Spanevello, A; Sulis, G; Tadolini, M; Tiberi, S; Vargas Vasquez, D; Viggiani, P; White, V; Zumla, A | 1 |
| Barry, CE; Blanchard, JS; Boshoff, HI; Hugonnet, JE; Tremblay, LW | 1 |
| Dauby, N; Mouchet, F; Muylle, I; Payen, MC; Sergysels, R | 1 |
| Clumeck, N; De Wit, S; Martin, C; Muylle, I; Payen, MC; Sergysels, R; Van Laethem, Y | 1 |
| Arthur, M; Dubée, V; Dubost, L; Ethève-Quelquejeu, M; Gutmann, L; Hugonnet, JE; Mainardi, JL; Marie, A; Triboulet, S | 1 |
| Alffenaar, JW; Bolhuis, MS; Centis, R; D'Ambrosio, L; De Lorenzo, S; Migliori, GB; Piana, A; Sotgiu, G; Spanevello, A; Tiberi, S; van Altena, R; Viggiani, P | 1 |
12 other study(ies) available for clavulanic acid and Extensively Drug-Resistant Tuberculosis
| Article | Year |
|---|---|
Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases.
Topics: Adult; Antitubercular Agents; Clavulanic Acid; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Follow-Up Studies; Humans; Male; Meropenem; Retrospective Studies; Time Factors; Treatment Outcome | 2018 |
Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of β-lactam-β-lactamase inhibitor combinations.
Topics: Amino Acid Substitution; Antitubercular Agents; beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Drug Therapy, Combination; Escherichia coli; Extensively Drug-Resistant Tuberculosis; Gene Expression; Humans; Meropenem; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Mycobacterium tuberculosis; Protein Engineering; Recombinant Proteins; Thienamycins | 2013 |
First series of patients with XDR and pre-XDR TB treated with regimens that included meropenen-clavulanate in Argentina.
Topics: Adult; Antitubercular Agents; Argentina; Clavulanic Acid; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Humans; Male; Meropenem; Middle Aged; Mycobacterium tuberculosis; Peru; Retrospective Studies; Sputum; Thienamycins; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Uruguay; Young Adult | 2015 |
Classification of antituberculosis drugs: a new proposal based on the most recent evidence.
Topics: Antitubercular Agents; Carbapenems; Clavulanic Acid; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Infectious Disease Medicine; Linezolid; Nitroimidazoles; Oxazoles; Practice Guidelines as Topic; Tuberculosis, Multidrug-Resistant; World Health Organization | 2015 |
Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
Topics: Antitubercular Agents; Clavulanic Acid; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Imipenem; Treatment Outcome | 2016 |
Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Topics: Adult; Antitubercular Agents; Clavulanic Acid; Extensively Drug-Resistant Tuberculosis; Female; Humans; Male; Meropenem; Retrospective Studies; Thienamycins; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2016 |
Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Topics: Adult; Antitubercular Agents; Clavulanic Acid; Cohort Studies; Comparative Effectiveness Research; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Sputum; Thienamycins; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2016 |
Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis.
Topics: Acylation; Antibiotics, Antitubercular; beta-Lactamase Inhibitors; beta-Lactamases; Catalytic Domain; Clavulanic Acid; Crystallography, X-Ray; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Extensively Drug-Resistant Tuberculosis; Humans; Kinetics; Mass Spectrometry; Meropenem; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Thienamycins | 2009 |
Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis.
Topics: Acetamides; Adolescent; Antitubercular Agents; Clavulanic Acid; Extensively Drug-Resistant Tuberculosis; Female; Humans; Linezolid; Meropenem; Oxazolidinones; Thienamycins; Treatment Outcome | 2011 |
Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Clavulanic Acid; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Mycobacterium tuberculosis; Salvage Therapy; Severity of Illness Index; Thienamycins; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult | 2012 |
Inactivation of Mycobacterium tuberculosis l,d-transpeptidase LdtMt₁ by carbapenems and cephalosporins.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Clavulanic Acid; Extensively Drug-Resistant Tuberculosis; Meropenem; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Peptidoglycan; Peptidyl Transferases; Thienamycins | 2012 |
Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.
Topics: Acetamides; Adult; Antitubercular Agents; Case-Control Studies; Clavulanic Acid; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Humans; Linezolid; Male; Meropenem; Middle Aged; Oxazolidinones; Thienamycins; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2013 |